Business Context and Reporting Period
This Form 8-K filing by Recursion Pharmaceuticals, Inc. (RXRX) covers the date of March 25, 2026. The report details a significant leadership transition within the company's medical leadership team.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Leadership Transition: Vicki Goodman, M.D., is appointed as the new Chief Medical Officer (CMO), effective April 6, 2026.
- Departure: David Mauro, M.D., Ph.D., is transitioning out of the CMO role.
- Transitional Arrangement: Dr. Mauro will remain with the company in an advisory capacity until May 29, 2026, to ensure a smooth handover.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk disclosures beyond the standard Regulation FD disclosure regarding the press release. The primary focus is the operational continuity of the medical leadership team.
Investor Verification Checklist
- Verify the effective date of Dr. Goodman's appointment (April 6, 2026) and Dr. Mauro's advisory end date (May 29, 2026).
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the CMO change.
- Confirm that no other executive departures or appointments were disclosed in this specific filing.